Merck blocks ‘safer’ gene therapy trials

Retroviral Integrations in Gene Therapy Trials

γ-Retroviral and lentiviral vectors allow the permanent integration of a therapeutic transgene in target cells and have provided in the last decade a delivery platform for several successful gene therapy (GT) clinical approaches. However, the occurrence of adverse events due to insertional mutagenesis in GT treated patients poses a strong challenge to the scientific community to identify the me...

Arthritis gene therapy trials reach phase II.

Gene therapy trials: a patient pathway.

This article describes ongoing gene therapy trials at University Hospital Birmingham NHS Trust for liver, head and neck and prostate cancer treatment. The authors suggest that this research programme might become an alternative option for patients who have not responded to conventional treatments.

Merck Animal Health

Lancaster R.T., Foxcroft, G.R., Boland, M.R, Edwards, S. and Gordon, I., 1985. Fertility of sows treated with exogenous estradiol and/or gonadotropins to control postweaning estrus. Anim. Reprod. Sci., 8:365-373 In the first of two experiments 28 multiparous sows were allocated to one of the following treatments two days after weaning at approximately 35 days postpartum: (1) untreated; (2) i.m....

Massachusetts General Hospital SAFER criteria for clinical trials and research.

M ajor depressive disorder (MDD) is considered a major public health issue related to considerable morbidity and disability. In addition, about half of patients with MDD will respond either partially or not at all to first-line antidepressant monotherapy, despite an adequate dosage and a sufficient duration of treatment. For these patients, there is a clear need to study next-step antidepressan...